Dyadic (DYAI) Highlights.
"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Adding Citius (CTXR) $0.55 to Watch List.
Best Presentation at Dawson James Conference.
We attended the Dawson James Conference on October 29th, which had over 20 medtech and biotech companies. The two...
Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Analyst Take: "Potential to be Revolutionary. Dyadic’s C1 shows potential in...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
INVESTOR PRESENTATION
LONGER TERM CHART
Client, see published reports for disclosure and disclaimer details.
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided...
Latest article
Adding BCM Resources Corporation (B.V) $0.27, Up 42%, to Watch List.
'Elephant Hunter' Dr. Sergei Diakov is Expanding Drill Footprint, to Outline a Potentially Massive Copper-Gold System Beneath the Surface.
Led by legendary geologist Dr. Sergei...
New Report on Sekur Private Data (SWISF). Palantir’s Open Secure AI.
Palantir CEO Alex Karp discusses open-weight artificial intelligence models, how he believes the technology should be regulated and why the U.S. should avoid Europe’s...
Replimune (REPL) Jumps 100%.
A Nifty $415 Million Gain (in an hour) for Shareholders.
Not out of the woods yet..
Short and to the point: We listened to whole meeting...
